Table 1 Baseline characteristics of the investigated hepatocellular carcinoma patients
Characteristic | Hepatectomy-TACE group (n = 116) | Hepatectomy Alone group (n = 118) | P-value |
|---|---|---|---|
Age [years; median (range)] | 44.0 (18–75) | 48.5 (18–74) | 0.112 |
Gender [cases (%)] | |||
 Male | 106 (91.4) | 106 (89.8) | 0.824 |
 Female | 10 (8.6) | 12 (10.2) | |
ECOG performance status [cases (%)] | |||
 0 | 48 (41.4) | 53 (44.9) | 0.794 |
 1 | 65 (56.0) | 63 (53.4) | |
 2 | 3 (2.6) | 2 (1.7) | |
Serum HBsAg [cases (%)] | |||
 Positive | 94 (81.0) | 101 (85.6) | 0.384 |
 Negative | 22 (19.0) | 17 (14.4) | |
Preoperative serum AFP [cases (%)] | |||
 < 25 ng/mL | 37 (31.9) | 36 (30.5) | 0.888 |
 ≥ 25 ng/mL | 79 (68.1) | 82 (69.5) | |
Hemoglobin (g/L; mean ± SD) | 142.3 ± 23.7 | 141.2 ± 24.4 | 0.711 |
Platelet (× 109/L; mean ± SD) | 205.2 ± 79.1 | 178.6 ± 80.0 | 0.119 |
Alanine aminotransferase (U/L; mean ± SD) | 55.3 ± 57.4 | 45.1 ± 27.9 | 0.086 |
Serum albumin (g/L; mean ± SD) | 41.4 ± 5.7 | 41.6 ± 3.4 | 0.741 |
Serum total bilirubin (mol/L; mean ± SD) | 14.4 ± 5.8 | 17.3 ± 24.6 | 0.212 |
Prothrombin time (s; mean ± SD) | 12.2 ± 1.2 | 12.2 ± 1.1 | 0.725 |
Child–Pugh grade [cases (%)] | |||
 Class A | 116 (100.0) | 116 (98.3) | 0.498 |
 Class B | 0 (0.0) | 2 (1.7) | |
Serum urea (mmol/L; mean ± SD) | 5.0 ± 1.6 | 5.2 ± 1.3 | 0.378 |
Serum creatinine (μmol/L; mean ± SD) | 78.1 ± 24.4 | 73.8 ± 15.5 | 0.114 |